54 related articles for article (PubMed ID: 38646256)
1. Occurrence of Epstein-Barr virus-associated plasmacytic lymphoproliferative disorder after antithymocyte globulin therapy for aplastic anemia: a case report with review of the literature.
Nakanishi R; Ishida M; Hodohara K; Okuno H; Yoshii M; Horinouchi A; Shirakawa A; Harada A; Iwai M; Yoshida K; Kagotani A; Yoshida T; Okabe H
Int J Clin Exp Pathol; 2014; 7(4):1748-54. PubMed ID: 24817974
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr-Virus-Related Lymphoproliferative Disorder in a Patient With Primary Myelofibrosis: A Case Report and Literature Review.
Oshima S; Inano S; Kitano T
Cureus; 2024 Mar; 16(3):e56586. PubMed ID: 38646256
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and pathological features of 13 children with Epstein-Barr virus-positive lymphoproliferative disease].
Chen TM; Deng ZJ; Hu B; Hu HL; Chen HY; Li SY; Liu G
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):759-764. PubMed ID: 30293280
[No Abstract] [Full Text] [Related]
4. Spontaneous regression of breast lymphoproliferative disorders after withdrawal of methotrexate in rheumatoid arthritis patients with Epstein-Barr virus infection: a case report and review of the literature.
Ogawa A; Nakagawa T; Kumaki Y; Hosoya T; Oda G; Mori M; Fujioka T; Kubota K; Onishi I; Uetake H
J Med Case Rep; 2022 Feb; 16(1):49. PubMed ID: 35125110
[TBL] [Abstract][Full Text] [Related]
5. Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With
Ishimura M; Eguchi K; Shiraishi A; Sonoda M; Azuma Y; Yamamoto H; Imadome KI; Ohga S
Front Pediatr; 2019; 7():183. PubMed ID: 31231620
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis.
Ishida M; Hodohara K; Yoshii M; Okuno H; Horinouchi A; Nakanishi R; Harada A; Iwai M; Yoshida K; Kagotani A; Yoshida T; Okabe H
Int J Clin Exp Pathol; 2013; 6(10):2237-41. PubMed ID: 24133604
[TBL] [Abstract][Full Text] [Related]
7. Cessation of methotrexate and a small intestinal resection provide a good clinical course for a patient with a jejunum perforation induced by a methotrexate-associated lymphoproliferative disorder: a case report.
Nomura M; Sumiya R; Ono H; Nagai T; Kumazawa K; Shimizu A; Endo D; Aoyanagi N
World J Surg Oncol; 2021 Jan; 19(1):4. PubMed ID: 33388058
[TBL] [Abstract][Full Text] [Related]
8. EBV-Gastritis Preceded the Development of Nasopharyngeal EBV (+) Diffuse Large B Cell Lymphoma in a Patient With Ruxolitinib-Induced Immunosuppression.
Puello Yocum B; Mesa H; Maratt JK; Ermel AC; Manchanda N; Popnikolov N
Int J Surg Pathol; 2023 Oct; 31(7):1340-1346. PubMed ID: 36734083
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.
Lebon D; Dujardin A; Caulier A; Joris M; Charbonnier A; Gruson B; Quint M; Castelain S; François C; Lacassagne MN; Guillaume N; Marolleau JP; Morel P
Leuk Res; 2023 Feb; 125():107005. PubMed ID: 36580876
[TBL] [Abstract][Full Text] [Related]
10. Myelofibrosis.
Passamonti F; Mora B
Blood; 2023 Apr; 141(16):1954-1970. PubMed ID: 36416738
[TBL] [Abstract][Full Text] [Related]
11. Genetic basis and molecular profiling in myeloproliferative neoplasms.
Luque Paz D; Kralovics R; Skoda RC
Blood; 2023 Apr; 141(16):1909-1921. PubMed ID: 36347013
[TBL] [Abstract][Full Text] [Related]
12. EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.
Toner K; Bollard CM
Blood; 2022 Feb; 139(7):983-994. PubMed ID: 34437680
[TBL] [Abstract][Full Text] [Related]
13. First case of classical Hodgkin-like EBV-positive lymphoproliferative disorder under ruxolitinib therapy.
Mouchel PL; Syrykh C; Laurent C; Tavitian S; Gauthier M
Am J Hematol; 2021 Jun; 96(6):755-756. PubMed ID: 33075158
[No Abstract] [Full Text] [Related]
14. EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis.
Prem S; Loach D; Lipton J; Kumar R; Gupta V
Blood Res; 2019 Dec; 54(4):282-284. PubMed ID: 31915655
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
